Search

Your search keyword '"Kahler-Ribeiro-Fontana, S"' showing total 3 results
Start Over Author "Kahler-Ribeiro-Fontana, S" Publisher elsevier
3 results on '"Kahler-Ribeiro-Fontana, S"'

1. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up

Author

Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, Galimberti, Viviana, Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, and Galimberti, Viviana

Abstract

Introduction: In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6–14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs). Methods: This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory. Results: Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3–12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8–93.2) and 81.0% (95% CI, 77.2–84.2) in the whole cohort, 92.0% (95% CI, 89.0–94.2) and 81.5% (95% CI, 76.9–85.2) in those initially cN0, 89.8% (95% CI, 85.0–93.2) and 80.1% (95% CI, 72.8–85.7) in those initially cN1/2. Conclusion: The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome.

Published
2021

2. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up

Author

Paolo Veronesi, Giovanni Corso, Viviana Galimberti, Vincenzo Bagnardi, Marco Colleoni, Mattia Intra, Giuseppe Viale, Sabrina Kahler-Ribeiro-Fontana, Chiara Maria Grana, Emilia Montagna, Luca Bottiglieri, Jorge Villanova Biasuz, Eliana La Rocca, Silvia Ratini, Fiorella Canegallo, Consuelo Morigi, Eleonora Pagan, Francesca Magnoni, Maria Cristina Leonardi, Elisa Vicini, Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, and Galimberti, V

Subjects
Time Factors, medicine.medical_treatment, Axillary recurrence, 0302 clinical medicine, Breast cancer, Neoadjuvant treatment, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Mastectomy, Sentinel node biopsy, medicine.diagnostic_test, Axillary, Dissection, General Medicine, Middle Aged, Sentinel node, Neoadjuvant Therapy, Survival Rate, medicine.anatomical_structure, Oncology, Chemotherapy, Adjuvant, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Cohort, Female, Sentinel Lymph Node, Adult, medicine.medical_specialty, Antineoplastic Agents, Breast Neoplasms, 03 medical and health sciences, Biopsy, medicine, Humans, Neoplasm Staging, Retrospective Studies, Sentinel Lymph Node Biopsy, business.industry, medicine.disease, Surgery, Radiation therapy, Axilla, Positron-Emission Tomography, Radiotherapy, Adjuvant, business, Follow-Up Studies
Abstract

Introduction In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6–14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs). Methods This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory. Results Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3–12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8–93.2) and 81.0% (95% CI, 77.2–84.2) in the whole cohort, 92.0% (95% CI, 89.0–94.2) and 81.5% (95% CI, 76.9–85.2) in those initially cN0, 89.8% (95% CI, 85.0–93.2) and 80.1% (95% CI, 72.8–85.7) in those initially cN1/2. Conclusion The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome.

Published
2021

3. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.

Author

Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, Intra M, Canegallo F, Ratini S, Leonardi MC, La Rocca E, Bagnardi V, Montagna E, Colleoni M, Viale G, Bottiglieri L, Grana CM, Biasuz JV, Veronesi P, and Galimberti V

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Axilla, Breast Neoplasms diagnostic imaging, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Mastectomy, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Positron-Emission Tomography, Radiotherapy, Adjuvant, Retrospective Studies, Sentinel Lymph Node diagnostic imaging, Sentinel Lymph Node surgery, Survival Rate, Time Factors, Antineoplastic Agents therapeutic use, Breast Neoplasms pathology, Breast Neoplasms therapy, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy
Abstract

Introduction: In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6-14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs)., Methods: This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory., Results: Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3-12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8-93.2) and 81.0% (95% CI, 77.2-84.2) in the whole cohort, 92.0% (95% CI, 89.0-94.2) and 81.5% (95% CI, 76.9-85.2) in those initially cN0, 89.8% (95% CI, 85.0-93.2) and 80.1% (95% CI, 72.8-85.7) in those initially cN1/2., Conclusion: The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome., Competing Interests: Declaration of competing interest All the authors have no conflicts of interest in regards to the conflict of this manuscript., (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results